India Globalization Capital Appoints Claudia Grimaldi to its Board of Directors
March 23 2022 - 4:55PM
Business Wire
India Globalization Capital, Inc. (NYSE American: IGC) announces
that the Board has appointed Ms. Claudia Grimaldi as a
non-independent Director, effective March 23, 2022. IGC now has 5
directors including a majority who are independent.
Ms. Grimaldi has been with IGC for almost 12 years with
increasing responsibilities including managing SEC and NYSE
filings, regulatory compliance, and disclosures. She is currently
Vice President, Principal Finance Officer, and Chief Compliance
Officer. She is also the Managing Director of Hamsa Biochem SAS,
our subsidiary in Colombia, as well as a director of our subsidiary
in India.
Ms. Grimaldi stated: “I hope to bring diversity of thought and
perspective to the IGC Board. I have seen IGC overcame many
obstacles and grow over the last 12 years. I feel that we are in a
great place with IGC-AD1 and its potential to alleviate
neuropsychiatric symptoms like agitation, anxiety, and depression
in patients with Alzheimer’s disease. Working towards this
possibility is a huge motivator for me and our team. I believe that
I can help meaningfully advance the Company’s commitment to
achieving ESG goals.”
Ms. Grimaldi graduated with a BA in Psychology with high honors
from Javeriana University, a top three university in Colombia, and
an MBA with high honors from Meredith College in North Carolina.
She has completed Executive Education courses on SEC compliance,
finance from UVA, and corporate governance from the Columbia
Business School. By the end of this calendar year, she plans to
complete the National Association of Corporate Directors (NACD)
Directorship Certification program. She is fluent in both English
and Spanish. Ms. Grimaldi’s experience, education, training, and
deep knowledge of the Company and its businesses, make her well
qualified to serve as a director on IGC’s Board.
About IGC:
India Globalization Capital, Inc. (IGC), headquartered in
Maryland, engages in the development of cannabinoid-based therapies
for healthcare applications. IGC recently completed the first Phase
1 safety and tolerability clinical trial for patients suffering
from Alzheimer’s disease using a THC-based investigational new drug
candidate. The Company also operates an infrastructure business
based in India. www.igcinc.us, www.igcpharma.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220323005972/en/
Claudia Grimaldi info@igcinc.us Phone: 301-983-0998
IGC Pharma (AMEX:IGC)
Historical Stock Chart
From Mar 2024 to Apr 2024
IGC Pharma (AMEX:IGC)
Historical Stock Chart
From Apr 2023 to Apr 2024